Octreotide
An FDA-approved somatostatin analogue used to treat acromegaly, carcinoid tumors, and severe diarrhea.
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
What is Octreotide?
Octreotide is a synthetic octapeptide analogue of somatostatin with a much longer half-life (1.5 hours vs 2 minutes for native somatostatin). It is FDA-approved for acromegaly, carcinoid syndrome, and VIPomas. It suppresses growth hormone, insulin, glucagon, and various GI hormones.
Why People Talk About It
Acromegaly treatment (excess GH)
StrongCarcinoid tumor symptom control
StrongSevere diarrhea management
StrongHow It Works
Octreotide mimics somatostatin, the body's natural 'off switch' for many hormones. It tells the pituitary and gut to reduce hormone production, which is helpful when tumors are causing hormone overproduction.
Common Questions
Safety Information
Common Side Effects
Cautions
- • Regular gallbladder monitoring recommended
- • May affect glucose metabolism
- • Cardiac conduction changes possible
- • Drug interactions with cyclosporine and insulin
What We Don't Know
Well-characterized safety profile with decades of clinical use.
Published Research
32 studiesThe influence of somatostatin analogues on the incidence of pancreatic fistulas and postoperative morbidity in patients undergoing pancreatic resection: A Bayesian network meta-analysis
Octreotide versus oral dietary modification for the treatment of chylous fistula following neck dissection: A systematic review and meta-analysis
An updated systematic review and meta-analysis of the use of octreotide for the prevention of postoperative complications after pancreatic resection
Octreotide for congenital and acquired chylothorax in newborns: A systematic review
Efficacy of the prophylactic use of octreotide for the prevention of complications after pancreatic resection: An updated systematic review and meta-analysis of randomized controlled trials
Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review
Cost-effectiveness comparison of prophylactic octreotide and pasireotide for prevention of fistula after pancreatic surgery
68Ga-DOTATATE Compared with 111In-DTPA-Octreotide and Conventional Imaging for Pulmonary and Gastroenteropancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis
Efficacy of vasopressin/terlipressin and somatostatin/octreotide for the prevention of early variceal rebleeding after the initial control of bleeding: a systematic review and meta-analysis
Role of octreotide in post chemotherapy and/or radiotherapy diarrhea: prophylaxis or therapy?
Primary renal carcinoid: treatment and prognosis
Meta-analysis on the effects of octreotide on tumor mass in acromegaly
Meta-analysis: somatostatin or its long-acting analogue, octreotide, for prophylaxis against post-ERCP pancreatitis
Octreotide for advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
Meta-analysis: octreotide prevents post-ERCP pancreatitis, but only at sufficient doses
Prophylactic octreotide administration does not prevent post-endoscopic retrograde cholangiopancreatography pancreatitis: a meta-analysis of randomized controlled trials
Use of octreotide for the prevention of pancreatic fistula after elective pancreatic surgery: a systematic review and meta-analysis
Long-acting somatostatin analog therapy of acromegaly: a meta-analysis
Octreotide for acute esophageal variceal bleeding: a meta-analysis
Meta-analysis: efficacy of therapeutic regimens in ongoing variceal bleeding
[Randomized trial and meta-analysis of somatostatin versus placebo in bleeding esophageal varices]
Somatostatin and octreotide in the management of acute variceal hemorrhage
Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis
Octreotide in variceal bleeding
Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review
A systematic literature review to evaluate extended dosing intervals in the pharmacological management of acromegaly
Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly
Comparison of 24 vs 72-hr octreotide infusion in acute esophageal variceal hemorrhage - A multi-center, randomized clinical trial
[(177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
Standard of Care Versus Octreotide in Angiodysplasia-Related Bleeding (the OCEAN Study): A Multicenter Randomized Controlled Trial
Octreotide Subcutaneous Depot for Acromegaly: A Randomized, Double-blind, Placebo-controlled Phase 3 Trial, ACROINNOVA 1
Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study
Always consult a qualified clinician
This information is for educational purposes. Peptide therapy should be guided by a licensed healthcare provider. Connect with a Noho clinician
Related Peptides
Quick Facts
- Class
- Somatostatin Analogue
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Mar 2026
- Citations
- 32PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.
Interested in this peptide? A Noho clinician can help determine if it's right for you.
Talk to a Clinician